BIOCYTOGEN PHARMA. H YC1 Financial Flexibility Index
BIOCYTOGEN PHARMA. H YC1 financial flexibility index. BIOCYTOGEN PHARMA. H YC1 (I54) has a Financial Flexibility Index of 0.30x as of December 2025. Free cash flow of €458.07 Million (operating CF €370.25 Million minus capex €87.82 Million) represents 0% of total liabilities (€1.54 Billion). See BIOCYTOGEN PHARMA. H YC1 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Financial flexibility index of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025. Historical Financial Flexibility Index trend for BIOCYTOGEN PHARMA. H YC1 across 5 annual periods. Check BIOCYTOGEN PHARMA. H YC1 (I54) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
BIOCYTOGEN PHARMA. H YC1 Financial Flexibility Index by Year (2021–2025)
BIOCYTOGEN PHARMA. H YC1 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for BIOCYTOGEN PHARMA. H YC1. For the full cash flow conversion analysis, see how efficiently does BIOCYTOGEN PHARMA. H YC1 generate cash.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.30x | €458.07 Million | €370.25 Million | €1.54 Billion | ▲ +88.2% |
| 2024 | 0.16x | €248.38 Million | €211.25 Million | €1.58 Billion | ▲ +423.0% |
| 2023 | 0.03x | €49.97 Million | €-76.65 Million | €1.66 Billion | ▲ +178.9% |
| 2022 | -0.04x | €-62.99 Million | €-303.27 Million | €1.65 Billion | ▲ +76.0% |
| 2021 | -0.16x | €-167.11 Million | €-365.78 Million | €1.05 Billion | — |